IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$13.03

Market cap

$2.12B

P/E Ratio

4.12

Dividend/share

N/A

EPS

$3.16

Enterprise value

$2.1B

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
IRWD's P/E is 64% below its last 4 quarters average of 11.5
Ironwood Pharmaceuticals's gross profit has increased by 3.7% QoQ
IRWD's revenue is up by 3.7% QoQ but it is down by 3.2% YoY
The quick ratio has dropped by 80% since the previous quarter and by 68% year-on-year
IRWD's debt is up by 4.4% year-on-year

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
162.9M
Market cap
$2.12B
Enterprise value
$2.1B
Valuations
Price to earnings (P/E)
4.12
Price to book (P/B)
4.12
Price to sales (P/S)
5.11
EV/EBIT
10.25
EV/EBITDA
10.1
EV/Sales
5.09
Earnings
Revenue
$413.02M
EBIT
$205.34M
EBITDA
$208.39M
Free cash flow
$227.38M
Per share
EPS
$3.16
Free cash flow per share
$1.4
Book value per share
$3.16
Revenue per share
$2.55
TBVPS
$6.22
Balance sheet
Total assets
$1.01B
Total liabilities
$495.46M
Debt
$475.62M
Equity
$511.76M
Working capital
$485.9M
Liquidity
Debt to equity
0.93
Current ratio
4.62
Quick ratio
4.62
Net debt/EBITDA
-0.09
Margins
EBITDA margin
50.5%
Gross margin
99.8%
Net margin
123.2%
Operating margin
50.2%
Efficiency
Return on assets
76.6%
Return on equity
294.8%
Return on invested capital
30.5%
Return on capital employed
23.5%
Return on sales
49.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-0.91%
1 week
-4.61%
1 month
3.33%
1 year
37.3%
YTD
14.4%
QTD
-0.23%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$413.02M
Gross profit
$412.13M
Operating income
$207.5M
Net income
$508.86M
Gross margin
99.8%
Net margin
123.2%
IRWD's operating margin is up by 33% year-on-year and by 14% since the previous quarter
The operating income has increased by 29% YoY and by 18% from the previous quarter
IRWD's revenue is up by 3.7% QoQ but it is down by 3.2% YoY
Ironwood Pharmaceuticals's gross profit has increased by 3.7% QoQ

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
4.12
P/B
4.12
P/S
5.11
EV/EBIT
10.25
EV/EBITDA
10.1
EV/Sales
5.09
IRWD's P/E is 64% below its last 4 quarters average of 11.5
IRWD's price to book (P/B) is 94% lower than its last 4 quarters average of 73.3
IRWD's P/S is 18% below its 5-year quarterly average of 6.2 but 14% above its last 4 quarters average of 4.5
IRWD's revenue is up by 3.7% QoQ but it is down by 3.2% YoY

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has surged by 181% QoQ
The return on sales has surged by 64% year-on-year and by 13% since the previous quarter
Ironwood Pharmaceuticals's ROIC has increased by 43% YoY and by 7% from the previous quarter
Ironwood Pharmaceuticals's return on equity has decreased by 27% QoQ

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 103% more than the total liabilities
The total assets has soared by 127% YoY and by 68% from the previous quarter
The quick ratio has dropped by 80% since the previous quarter and by 68% year-on-year
IRWD's debt is 7% smaller than its equity
The company's debt to equity has surged by 108% YoY but it has shrunk by 78% QoQ
IRWD's debt is up by 4.4% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.